Bio


Dr. Jacquelyn Callander is a fellowship-trained rhinologist and endoscopic skull base surgeon at Stanford Health Care. She is also a clinical assistant professor in the Department of Otolaryngology – Head & Neck Surgery, Division of Rhinology & Endoscopic Skull Base Surgery at Stanford University School of Medicine.

Dr. Callander provides comprehensive care for patients with disorders of the nose, sinuses, and skull base. She treats chronic rhinosinusitis with and without nasal polyps, chronic rhinitis, nasal obstruction, cerebrospinal fluid leaks, and cancerous and noncancerous sinonasal and skull base tumors. Dr. Callander offers a range of medical and surgical treatment options. For conditions involving the skull base or orbit (eye socket), she works closely with colleagues in neurosurgery and ophthalmology to provide coordinated, multidisciplinary care.

Dr. Callander takes a thoughtful, individualized approach to care, with an emphasis on clear communication and shared decision-making. She strives to help patients understand their condition and select a treatment plan that reflects their symptoms, priorities, and long-term health.

Dr. Callander’s research focuses on developing biomarkers to better characterize inflammatory subtypes of chronic rhinosinusitis to personalize treatments. She also studies the genomic changes that drive sinonasal tumors and strategies for improving outcomes in endoscopic sinus and skull base surgeries. Dr. Callander’s work has been published in numerous peer-reviewed journals and she has presented at national and international scientific meetings. She is also dedicated to teaching medical students, residents, and fellows and contributing to national educational resources for future otolaryngologists.

Dr. Callander is a member of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), the American Rhinologic Society (ARS), and the North American Skull Base Society.

Clinical Focus


  • Otolaryngology

Academic Appointments


  • Clinical Assistant Professor, Otolaryngology (Head and Neck Surgery)

Honors & Awards


  • Top Clinical Abstracts, ARS at Combined Otolaryngology Spring Meetings (2025)
  • Steinhart Scholarship Award, UCSF School of Medicine (2020)
  • Resident Research Fund Grant, UCSF School Medicine (2022-2023)
  • Krevans Award for Clinical Excellence, Zuckerberg San Francisco General Hospital (2021)
  • First-Place Clinical Research, Bay Area Residents’ Research Symposium (2024)
  • First-Place and Third-Place Research Projects, Francis A. Sooy, MD Resident Research Symposium, UCSF Department of Otolaryngology – Head and Neck Surgery (2024, 2025)
  • Exceptional Physician Award, UCSF Health (2025)
  • Carolyn L. Kuckein Student Research Fellowship, Alpha Omega Alpha Honor Society (2019)
  • Diversity Fellowship, American Rhinologic Society (ARS) (2025-2026)

Boards, Advisory Committees, Professional Organizations


  • Member, North American Skull Base Society (2026 - Present)
  • Member, American Rhinologic Society (2023 - Present)
  • Member, American Academy of Otolaryngology – Head and Neck Surgery (2020 - Present)

Professional Education


  • Residency: UCSF Dept of Otolaryngology Head and Neck Surgery (2025) CA
  • Medical Education: University of California at San Francisco School of Medicine (2020) CA

All Publications


  • An exploratory study of the effect of metformin on the whole blood transcriptome of nondiabetic older adults with age-related macular degeneration. GeroScience Chen, X., Zhang, Y. S., Yan, D., Doan, T., Shen, L. L., Taha, A. T., Yang, D., Psaras, C., Callander, J. K., Xin, N. Y., Shivkumar, A., Fawzi, A. A., Yiu, G., Telander, D. G., Leung, L. B., Flaxel, C., Newman, J. C., Keenan, J. D., Stewart, J. M. 2026

    Abstract

    Metformin has received increasing attention for benefits beyond blood glucose lowering. The purpose of this study was to identify changes in whole blood transcriptome from a course of metformin in a randomized trial (NCT02684578) of nondiabetic older adults with age-related macular degeneration (AMD). We included patients who were ≥ 55 years of age, nondiabetic, and had geographic atrophy due to AMD. We excluded patients with metformin use for another reason, reduced renal or liver function, or other vitreoretinal diseases. Participants were randomized to metformin or control. The metformin group was prescribed 1000 mg metformin twice daily for 18 months. All eligible patients were approached for consent to blood sample collection. We performed metagenomic sequencing on whole blood samples and conducted differential expression analysis. Fifteen patients underwent blood collection, with eight in the metformin group and seven in the control group. No individual gene achieved statistical significance of difference between groups after correction for multiple comparisons. As a secondary, hypothesis-generating analysis, canonical pathway analysis found downregulation of interferon α/β signaling (P = 0.003, z score = -2.4), cell junction organization (P = 0.03, z score = -2.2), and epithelial mesenchymal transition pathways in the metformin group (P = 0.02, z score = -2.2). There was possible inhibition of upstream proinflammatory molecules and activation of anti-inflammatory molecules by metformin. In this small sub-study of a randomized trial, no gene was significantly changed after metformin exposure. Pathway enrichment analysis identified signals potentially consistent with metformin-associated modulation of "inflammaging" and other biological pathways which require validation in larger cohorts.

    View details for DOI 10.1007/s11357-026-02593-1

    View details for PubMedID 42900294

    View details for PubMedCentralID 3736576

  • Eosinophil Peroxidase as a Dynamic Indicator of Treatment Response in Eosinophilic Chronic Rhinosinusitis. International forum of allergy & rhinology Callander, J. K., Charbit, A. R., Marshall, C., Khanna, K., Pletcher, S. D., Gurrola, J. G., Murr, A. H., Tang, M., Goldberg, A. N., Loftus, P. A. 2025

    Abstract

    Eosinophil peroxidase (EPX) in nasal mucus correlates with markers of type 2 inflammation and tissue eosinophilia in chronic rhinosinusitis (CRS). This study evaluated EPX as a dynamic biomarker across treatment modalities and its potential prognostic value in eosinophilic CRS.Patients with bilateral CRS undergoing treatment with endoscopic sinus surgery (ESS) or dupilumab injections, as well as non-CRS controls undergoing endoscopic endonasal pituitary surgery were prospectively enrolled. Nasal cytology brushings from the middle meatus were collected pre-and post-treatment, except in the dupilumab group (sampled once after stabilization on medication). EPX was quantified via ELISA and correlated with clinical data.Twenty-nine CRS patients and 7 non-CRS controls were included. EPX levels decreased post-treatment in both treatment groups. Median paired change was -233.5 ng/µl (CRS ESS group, p = 0.015) and 0 ng/µl (non-CRS control group, p = 0.57). The difference of medians (non-paired) in the dupilumab-treated CRS group as compared to the pre-treatment CRS group was -460.9 ng/µl (p = 0.027). A strong negative correlation was observed between pre-treatment EPX concentration and ΔSNOT-22 score (Spearman's p = 0.70, p = 0.038), indicating that higher pre-treatment EPX levels were associated with greater improvements in SNOT-22 scores.EPX levels are elevated in CRS and decline with treatment. Higher baseline EPX may predict greater post-treatment symptom improvement, supporting EPX as a marker of disease activity and treatment response in CRS.Eosinophil peroxidase (EPX) correlates with local type 2 inflammation and may serve as a noninvasive biomarker of eosinophilic chronic rhinosinusitis. EPX declines after surgery and dupilumab, highlighting its potential to track treatment response. High baseline EPX predicts patients likely to achieve a clinically meaningful Sinonasal Outcome Test-22 change.

    View details for DOI 10.1002/alr.70076

    View details for PubMedID 41317131

  • Surgical Experience and Validation of the "Bow Tie" Trilayer Graft Technique for Closure of Anterior Skull Base Defects LARYNGOSCOPE INVESTIGATIVE OTOLARYNGOLOGY Callander, J. K., Erickson, T. S., Abdulbaki, H., Theodosopoulos, P. V., Aghi, M. K., Goldschmidt, E. D., El-Sayed, I. H., Gurrola, J. G. 2025; 10 (5)

    View details for DOI 10.1002/lio2.70281

    View details for Web of Science ID 001591894300001

  • Is There Utility in Testing Pathologic Specimen for HPV in Sinonasal Inverted Papilloma? The Laryngoscope Callander, J. K., Patel, Z. M. 2025

    View details for DOI 10.1002/lary.70053

    View details for PubMedID 40814726

  • Rhinologic Conditions of Pregnancy: A Retrospective Cohort Study OTO OPEN Eltawil, Y., Callander, J. K., Loftus, P. A. 2025; 9 (2)

    View details for DOI 10.1002/oto2.70114

    View details for Web of Science ID 001476713000001

  • Response to the Editor Regarding: "In Office Sampling of Eosinophil Peroxidase to Diagnose Eosinophilic Chronic Rhinosinusitis" INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY Callander, J. K., Charbit, A. R., Khanna, K., Fahy, J. V., Tang, M., Liegeois, M., Pletcher, S. D., Goldberg, A. N., Gurrola II, J. G., Murr, A. H., Butrymowicz, A., Loftus, P. A. 2025; 15 (3): 367-368

    View details for DOI 10.1002/alr.23554

    View details for Web of Science ID 001509987200002

    View details for PubMedID 39998482

  • Social capital as a catalyst for gender inequality: A scoping review of networking disparities in academic medicine. Cancer Callander, J. K., Johnson, D. E., Grandis, J. R. 2025; 131 (1): e35667

    Abstract

    Gender disparities in academic medicine persist despite gender parity among medical school graduates. Women remain underrepresented in higher academic ranks and leadership roles, with significant differences in retention, promotion, and compensation. In this scoping review, the authors explore the role of networking and social capital in exacerbating these disparities. The literature reviewed highlights the importance of networking in obtaining leadership roles, decreasing social isolation, and enhancing retention. Sponsorship, distinct from mentorship, is vital for career development and has a direct impact on professional growth. However, women are often under-sponsored compared with men, limiting their access to influential networks. In addition, virtual networking platforms and women-focused organizations offer promising alternatives to traditional, male-dominated networking activities. Despite the progress made, informal networking practices and gender biases continue to exclude women from key opportunities. These findings underscore the need for targeted interventions aimed at enhancing the social capital of women in academic medicine to help close the gender gap. Proposed interventions prime for further evaluation include the implementation of formal sponsorship programs, the development of structured networking opportunities, and the promotion of women-focused organizations.

    View details for DOI 10.1002/cncr.35667

    View details for PubMedID 39612169

    View details for PubMedCentralID PMC12302186

  • External Approaches to the Paranasal Sinuses Rhinology: Diseases of the Nose, Sinuses, and Skull Base Goldberg, A. N., Callander, J. K., Murr, A. H. 2025
  • Minimally Invasive Sternocleidomastoid Muscle Thinning for Cervical Feminization FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE Bhethanabotla, R. M., Callander, J. K., Wulu, J. A., Knott, P. D. 2025; 27 (1): 91-97

    Abstract

    Background: At present, there is no gender-affirming facial surgery that offers feminization of the lateral neck. Objective: To demonstrate reliable relationship between the great auricular nerve point (GAP) and spinal accessory nerve along the sternocleidomastoid muscle (SCM) in human anatomical specimens and demonstrate feasibility of muscle transection in one transgender female patient. Methods: A total of 14 human anatomical specimen dissections were performed to determine if a transection of the SCM perpendicular to the GAP could be performed without potential compromise of the spinal accessory nerve. The surgical course of a patient who underwent transection is discussed. Results: Mean distance from the GAP to the accessory nerve at the posterior border of the sternocleidomastoid was 1.01 ± 0.54 cm, consistent with results from prior studies. In both the human anatomical specimens and the patient, sternocleidomastoid muscles were divided without injury to accessory nerve. The patient's neck girth was reduced by an average of 7 cm at 2 years post-operatively. Conclusion: Transection with distal denervation of the SCM by identifying the relationship between the GAP and accessory nerve is a feasible method of feminizing the lateral neck to improve cosmetic satisfaction while minimizing the risks of cervical neurovascular injury.

    View details for DOI 10.1089/fpsam.2024.0161

    View details for Web of Science ID 001370481000001

    View details for PubMedID 39636398

  • METformin for the MINimization of Geographic Atrophy Progression (METforMIN): A Randomized Trial. Ophthalmology science Shen, L. L., Keenan, J. D., Chahal, N., Taha, A. T., Saroya, J., Ma, C. J., Sun, M., Yang, D., Psaras, C., Callander, J., Flaxel, C., Fawzi, A. A., Schlesinger, T. K., Wong, R. W., Bryan Leung, L. S., Eaton, A. M., Steinle, N. C., Telander, D. G., Afshar, A. R., Neuwelt, M. D., Lim, J. I., Yiu, G. C., Stewart, J. M. 2024; 4 (3): 100440

    Abstract

    Metformin use has been associated with a decreased risk of age-related macular degeneration (AMD) progression in observational studies. We aimed to evaluate the efficacy of oral metformin for slowing geographic atrophy (GA) progression.Parallel-group, multicenter, randomized phase II clinical trial.Participants aged ≥ 55 years without diabetes who had GA from atrophic AMD in ≥ 1 eye.We enrolled participants across 12 clinical centers and randomized participants in a 1:1 ratio to receive oral metformin (2000 mg daily) or observation for 18 months. Fundus autofluorescence imaging was obtained at baseline and every 6 months.The primary efficacy endpoint was the annualized enlargement rate of the square root-transformed GA area. Secondary endpoints included best-corrected visual acuity (BCVA) and low luminance visual acuity (LLVA) at each visit.Of 66 enrolled participants, 34 (57 eyes) were randomized to the observation group and 32 (53 eyes) were randomized to the treatment group. The median follow-up duration was 13.9 and 12.6 months in the observation and metformin groups, respectively. The mean ± standard error annualized enlargement rate of square root transformed GA area was 0.35 ± 0.04 mm/year in the observation group and 0.42 ± 0.04 mm/year in the treatment group (risk difference = 0.07 mm/year, 95% confidence interval = -0.05 to 0.18 mm/year; P = 0.26). The mean ± standard error decline in BCVA was 4.8 ± 1.7 letters/year in the observation group and 3.4 ± 1.1 letters/year in the treatment group (P = 0.56). The mean ± standard error decline in LLVA was 7.3 ± 2.5 letters/year in the observation group and 0.8 ± 2.2 letters/year in the treatment group (P = 0.06). Fourteen participants in the metformin group experienced nonserious adverse events related to metformin, with gastrointestinal side effects as the most common. No serious adverse events were attributed to metformin.The results of this trial as conducted do not support oral metformin having effects on reducing the progression of GA. Additional placebo-controlled trials are needed to explore the role of metformin for AMD, especially for earlier stages of the disease.Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

    View details for DOI 10.1016/j.xops.2023.100440

    View details for PubMedID 38284098

    View details for PubMedCentralID PMC10810745

  • In office sampling of eosinophil peroxidase to diagnose eosinophilic chronic rhinosinusitis INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY Callander, J. K., Charbit, A. R., Khanna, K., Fahy, J. V., Tang, M., Liegeois, M., Pletcher, S. D., Goldberg, A. N., Gurrola II, J. G., Murr, A. H., Butrymowicz, A., Loftus, P. A. 2025; 15 (1): 36-44

    Abstract

    Practical biomarkers for endotypic characterization of chronic rhinosinusitis (CRS) remain elusive, hindering clinical utility. Eosinophil peroxidase (EPX) is an enzyme released by activated eosinophils. The objective of this study was to evaluate a clinic EPX assay as a marker of eosinophilic CRS.Subjects with and without CRS presenting to a tertiary care rhinology clinic were prospectively enrolled, and nasal cytology brushings were collected from the middle meatus during in-clinic nasal endoscopy. ELISA assay was used to quantify EPX levels, and a customized multiplex immunoassay was used to quantify inflammatory cytokine mediators. Findings were correlated with clinical data.Forty-two subjects were enrolled, including 31 CRS subjects and 11 controls. Median EPX levels were 125.0 ng/mL (standard deviation [SD] 1745.8) and 6.5 ng/mL (SD 99.0) for CRS group and controls, respectively (p = 0.003). EPX levels were associated with history of asthma (p = 0.015), allergies (p = 0.028), polyps (p = 0.0006), smell loss (p = 0.006), and systemic eosinophilia or elevated immunoglobulin E (p ≤ 0.0001). Twenty-eight subjects from both the CRS and control groups had prior pathology for comparison, with histologic confirmation of local tissue eosinophilia (>10 eosinophils/hpf) in 11 subjects. This subgroup had a median EPX level of 967.5 ng/mL compared to 10.6 ng/mL in 17 subjects without local tissue eosinophilia (p = 0.0008). EPX levels were positively correlated to interleukin-5 levels (p = 0.0005).EPX levels can be measured via well-tolerated in-clinic collection of nasal mucus. EPX levels are associated with clinical markers of type 2 inflammation and tissue eosinophilia and may provide a valuable diagnostic tool to delineate eosinophilic CRS.

    View details for DOI 10.1002/alr.23448

    View details for Web of Science ID 001312184000001

    View details for PubMedID 39269218

    View details for PubMedCentralID PMC11697230

  • Transcutaneous Retrobulbar Amphotericin B Injection for Invasive Fungal Sinusitis with Orbital Involvement: A Systematic Review AMERICAN JOURNAL OF RHINOLOGY & ALLERGY Abdulbaki, H., Callander, J. K., Fastenberg, J. H., Russell, M. S., Vagefi, M., Kersten, R. C., Loftus, P. A. 2024; 38 (5): 339-353

    Abstract

    Orbital involvement of invasive fungal sinusitis (IFS) is an ominous prognostic marker that should prompt rapid intervention. Transcutaneous retrobulbar administration of amphotericin B (TRAMB) is an off-label adjunctive treatment that can increase drug penetrance into diseased orbital tissue. To date, there is a lack of consensus regarding the use of TRAMB for treatment of IFS with orbital involvement.This systematic review aims to synthesize the indications, efficacy, and potential complications of TRAMB.PubMed, EMBASE, and Web of Science databases were probed for systematic review. Article search was conducted through June 2023 using the keywords "invasive fungal sinusitis," "invasive fungal rhinosinusitis," "rhino-orbital mucormycosis," "rhinosinusitis," "orbital," "retrobulbar," and "amphotericin."In suitable cases as determined by radiologic and clinical evaluation, TRAMB administration has the potential to improve orbital salvage rates and improve versus stabilize visual acuity. Treatment complications are more likely with deoxycholate than with liposomal amphotericin formulations. The existing literature describing use of TRAMB is limited due to its retrospective nature, but the increase in IFS cases since 2020 due to the COVID pandemic has broadened the literature.TRAMB is an effective adjunctive treatment in IFS with mild-to-moderate orbital involvement when used in combination with standard of care debridement, systemic antifungal therapy, and immunosuppression reversal. Prospective longitudinal studies and multi-institutional randomized trials are necessary to determine the definitive utility of TRAMB.

    View details for DOI 10.1177/19458924241254422

    View details for Web of Science ID 001228842000001

    View details for PubMedID 38772559

  • Treatment of the Nose for Patients with Sleep Apnea OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA Callander, J. K., Chang, J. L. 2024; 57 (3): 491-500

    Abstract

    Nasal obstruction is common in patients with obstructive sleep apnea (OSA) and may variably impact symptoms and severity of OSA. It is associated with decreased continuous positive airway pressure (CPAP) compliance, and both medical and surgical management of nasal obstruction have resulted in increased CPAP adherence. Treatment of OSA with comorbid rhinitis via topical nasal steroids demonstrates a beneficial impact on daytime sleepiness. Isolated nasal surgery has been shown to result in decreased daytime sleepiness and snoring, with minimal effect on OSA severity.

    View details for DOI 10.1016/j.otc.2023.11.002

    View details for Web of Science ID 001236512500002

    View details for PubMedID 38072728

  • Laryngeal Hyposensitivity in Obstructive Sleep Apnea LARYNGOSCOPE Callander, J. K., Kandahari, N., Strohl, M. P., Cheung, S. W., Chang, J. L. 2024; 134 (8): 3856-3861

    Abstract

    Impaired laryngopharyngeal sensation has been implicated in obstructive sleep apnea (OSA) and may play an important pathophysiological role. We evaluated sensory function in OSA by examining the laryngeal adductor reflex (LAR) response rate and temporal profile to tactile stimulation.Laryngeal sensation testing was performed in awake adults with and without diagnosed OSA by stimulating the medial aryepiglottic fold or arytenoid using 30-mm 5-0 and 4-0 nylon Cheung-Bearelly monofilaments. Video analysis by two independent reviewers evaluated for the presence of the LAR in response to satisfactory stimuli and LAR latency to vocal fold adduction.Twenty-six OSA and 12 control subjects were tested with 270 satisfactory stimuli. The mean full LAR response rate to 4-0 stimulation was 38.3% in OSA vs 86.9% in control subjects (p <0.001) and to 5-0 stimulation was 27% in OSA vs 63.9% in control subjects (p  <0.001). The mean LAR latency to vocal fold closure in OSA was 123.7 ms (SD 35.8) vs 156.4 ms (SD 44.3) in control (p = 0.04) subjects. OSA LAR latency was positively correlated with the apnea-hypopnea index (r = 0.30; p = 0.008).The OSA group exhibited reduced LAR response rates and shortened LAR latency, where latency was correlated with disease severity. Laryngeal hyposensitivity was affirmed and changes to LAR sensorimotor temporal dynamics were revealed. These pathophysiological alterations to the LAR may be accounted for by decreased somatosensory receptor sensitivity, increased sympathetic tone, and reorganized brain stem function in OSA.3 Laryngoscope, 134:3856-3861, 2024.

    View details for DOI 10.1002/lary.31415

    View details for Web of Science ID 001193983700001

    View details for PubMedID 38554047

  • Prognostic risk factors of buccal squamous cell carcinoma: A case-control study HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK Callander, J. K., Souza, S. S., Eltawil, Y., El-Sayed, I. H., George, J. R., Ha, P., Ryan, W. R., Xu, M., Heaton, C. M. 2024; 46 (10): 2398-2406

    Abstract

    To describe the clinicopathologic presentation of buccal squamous cell carcinoma and identify risks factors for recurrence and overall survival.This is a retrospective case-control study of patients with oral cavity squamous cell carcinoma (OCSCC) treated at a single tertiary care center between 2010 and 2022. All patients with buccal subsite OCSCC treated during this time frame were included and paired with a randomly selected age and gender matched patient with non-buccal OCSCC. Relevant data was collected via chart review.Seventy-seven patients with buccal SCC were matched with 77 non-buccal OCSCC controls. The median follow-up time was 27 months (IQR 14-61). Median age was 67 years (IQR 57-75) and 53% of the cohort was female. Twenty (26%) buccal SCC patients experienced a recurrence versus 19 (25%) in the controls. Age ≥65-years-old increased odds of all-cause mortality in the buccal SCC group, but not in the control group. Perineural invasion and positive margins increased odds of recurrence in the buccal group only. Overall survival and progression-free survival did not differ between the groups, despite a greater number of T2 buccal tumors and T1 non-buccal tumors.Buccal SCC presents at a higher T stage than other oral cavity SCC subsite and may exhibit variance in the pathologic risk factors that predict poor outcomes versus non-buccal OCSCC. Despite these relatively minor differences, however, oncologic outcomes between these groups were similar.

    View details for DOI 10.1002/hed.27705

    View details for Web of Science ID 001173359700001

    View details for PubMedID 38411290

  • Video-Based Decision Aids Improve Sleep Surgery Decision-Making: A Randomized Controlled Trial LARYNGOSCOPE Gulati, A., Abdulbaki, H., Callander, J. K., Cai, Y., Chang, J. L. 2024; 134 (6): 2958-2963

    Abstract

    Decisional conflict (DC) is high in obstructive sleep apnea (OSA) surgical candidates interested in positive airway pressure (PAP) alternatives. We evaluated the impact of pre-consultation video decision aids on patient DC and decision readiness.Prior to consultation for PAP alternatives, adult OSA patients were enrolled and completed a questionnaire querying DC (scored 0 [no conflict]-100 [high conflict]) and decision readiness. Those considering ≥3 treatment options were categorized as "high-conflict." Patients were randomized to either an intervention group with video review about PAP and surgical options prior to their visit or to a control group that received no video review. Audio recordings of clinic visits were analyzed for patient engagement.Twenty-five participants (control: n = 12, intervention: n = 13) were found to have comparably high DC (mean score: 40.0). Both groups experienced post-visit improvements in DC scores (post-consult: 25.2, p = 0.003) which did not differ between the two groups (intervention: 20.5 ± 15.1 vs. control: 11.7 ± 12.1 points, p = 0.13). The intervention group showed significant improvement in decision-making stage after the visit, with 72.7% "close to selecting an option" (p = 0.04) versus 41.7% in the control group. Use of videos was not associated with any differences in patient satisfaction, engagement, or decision to pursue surgery (all p > 0.05). High-conflict patients (n = 5) who reviewed pre-visit videos (intervention sub-group) spoke fewer words during the visit (687 ± 139 vs. 1120 ± 389 words, p = 0.047) and had shorter visit times (18.7 ± 2.9 vs. 24.3 ± 3.1 min, p = 0.02) than high-conflict control patients.Patients have high levels of DC when considering PAP alternatives. Use of video decision aids prior to sleep surgery consultation may improve the treatment decision-making process.2 Laryngoscope, 134:2958-2963, 2024.

    View details for DOI 10.1002/lary.31156

    View details for Web of Science ID 001105060800001

    View details for PubMedID 37965946

  • Management of Newborn Traumatic Nasal Deformity with a Nostril Retainer LARYNGOSCOPE Civantos, A. M., Callander, J., Czechowicz, J., Jacobson, L., Rosbe, K. W. 2024; 134 (3): 1469-1471

    View details for DOI 10.1002/lary.30956

    View details for Web of Science ID 001065136200001

    View details for PubMedID 37642380

  • Spondylodiscitis and Spinal Epidural Abscess After Transoral Robotic Surgery Radical Tonsillectomy OTO OPEN Callander, J. K. K., Clark, A. J. J., Dillon, W., Ryan, W. R. R. 2023; 7 (2)

    View details for DOI 10.1002/oto2.61

    View details for Web of Science ID 001012139800001

  • Symptom Outcomes After Sialendoscopy-Assisted Salivary Duct Surgery: A Prospective 6-Year Study LARYNGOSCOPE Callander, J. K., Plonowska-Hirschfeld, K., Gulati, A., Chang, J. L., Ryan, W. R. 2023; 133 (4): 792-800

    Abstract

    The objective is to evaluate the long-term impact of sialendoscopic-assisted salivary duct surgery (SASDS) on sialadenitis symptoms using the Chronic Obstructive Sialadenitis Symptoms (COSS) questionnaire.The COSS questionnaire, which scores symptoms on a 0-100 scale, was administered prospectively to adult patients pre-operatively, 1-year, and 6-years post-operatively. We examined COSS scores and categories representing complete (<10), partial (10-25), and no (>25) resolution of symptoms with attention to factors significantly associated with incomplete resolution (≥10).Approximately 6-years after SASDS, 111 patients reported scores for 128 symptomatic glands (72 with sialolithiasis, 56 without sialolithiasis). For glands with sialolithiasis, the median COSS score pre-SASDS was 27.5 (interquartile range [IQR]: 13.5-43), which was significantly reduced to 1.0 (IQR: 0-5.5) at 1-year and 1.5 (IQR 0-5) at 6-years postoperatively. Glands without sialolithiasis had a median COSS score of 40.5 (IQR: 23-52.5) preoperatively, that significantly reduced to 13.5 (IQR 5-21) at 1-year and 14 (IQR 6.5-25.5) at 6-years post-operatively. There was no significant difference in scores from 1- to 6-years. Intraoperative presence of sialolith, absence of stenosis, stenosis in the distal duct, and submandibular gland involvement were significant predictors of complete resolution of symptoms at 6-years.Approximately 6-years after SASDS for sialadenitis, the majority of patients have durable symptom improvement. The sialolithiasis group had higher rates of complete resolution compared to the non-sialolithiasis group. Presence of ductal stenosis on sialendoscopy, non-distal stenoses, and parotid gland involvement were risk factors for persistent long-term sialadenitis symptoms. Laryngoscope, 133:792-800, 2023.

    View details for DOI 10.1002/lary.30294

    View details for Web of Science ID 000826509800001

    View details for PubMedID 35848880

  • Networking practices and gender inequities in academic medicine: Women's and men's perspectives ECLINICALMEDICINE Murphy, M., Callander, J. K., Dohan, D., Grandis, J. R. 2022; 45
  • Mentoring Relationships and Gender Inequities in Academic Medicine: Findings From a Multi-Institutional Qualitative Study ACADEMIC MEDICINE Murphy, M., Record, H., Callander, J. K., Dohan, D., Grandis, J. R. 2022; 97 (1): 136-142

    Abstract

    This study examined how mentoring relationships may reinforce or mitigate gender inequities in academic medicine.In-depth, semistructured interviews with medical school faculty members (52 women and 52 men) were conducted at 16 institutions across the United States in 2019. Institutions were recruited using a purposive sampling strategy to seek diversity in geography, ownership (private or public), and prestige. Within institutions, purposive sampling was used to recruit equal numbers of women and men and to seek diversity in degree type (MD, PhD), age, and career stage. A coding scheme was developed through iterative analysis of the interview transcripts. All interview transcripts were then coded with the goal of identifying intersections between mentorship and experiences of and responses to gender inequities.Four key themes at the intersection of mentoring relationships and gender inequities were identified. (1) Both women and men became aware of gender inequities in academic medicine through relationships with women mentors and mentees. (2) Both women and men mentors recognized the challenges their female mentees faced and made deliberate efforts to help them navigate an inequitable environment. (3) Both women and men mentors modeled work-family balance and created family friendly environments for their mentees. (4) Some women, but no men, reported being sexually harassed by mentors.This study shows that mentoring relationships may be a context in which gender inequities are acknowledged and mitigated. It also shows that mentoring relationships may be a context in which gender inequities, such as sexual harassment, may occur. Sexual harassment in academic medicine has been widely documented, and gender inequity in academic medicine has proved persistent. While mentoring relationships may have the potential to identify and mitigate gender inequities, this study suggests that this potential remains largely unrealized.

    View details for DOI 10.1097/ACM.0000000000004388

    View details for Web of Science ID 000771674900034

    View details for PubMedID 34495884

  • Women's Experiences of Promotion and Tenure in Academic Medicine and Potential Implications for Gender Disparities in Career Advancement A Qualitative Analysis JAMA NETWORK OPEN Murphy, M., Callander, J. K., Dohan, D., Grandis, J. R. 2021; 4 (9): e2125843

    Abstract

    Gender disparities in career advancement in academic medicine have persisted despite gender parity in medical school matriculation. Although numerous explanations for this gap exist, little is known about women's experiences of promotion and tenure in academic medicine.To examine women's experiences of promotion and tenure in academic medicine to uncover mechanisms associated with the gender disparity in career advancement.In this qualitative study, 52 in-depth, semistructured interviews with women academic medicine faculty members were conducted in 2019. The 52 participants were drawn from 16 medical schools across the US. Institutions were selected using a purposive sampling strategy to seek diversity of geography and ownership (private or public). Within institutions, purposive and snowball sampling were used to seek diversity with respect to respondents' degree type (MD, PhD, and MD and PhD), age, and career stage. Interview transcripts were analyzed using qualitative thematic analysis. Data analysis was performed from March to December 2020.Themes and subthemes in participants' experiences of promotion and tenure.The 52 women in this study ranged in age from 34 to 82 years (mean [SD] age, 54.0 [10.7] years). Eighteen respondents (34.6%) held an MD, 4 (7.7%) held both an MD and PhD, and 30 (57.7%) held a PhD. Fourteen respondents (26.9%) were assistant professors at the time of the study, 8 (15.4%) were associate professors, and 30 (57.7%) were full professors. Four main themes within participants' experiences of promotion and tenure that pertain to gender inequities were identified: ambiguous or inconsistent criteria for promotion or tenure; lack of standard processes for reviewing applications and making decisions; vulnerability to malicious behavior of senior faculty, department chairs, and division chiefs; and women seeing men have different experiences of advancement.The respondents' experiences of promotion and tenure suggest that promotion and tenure processes may be characterized by inconsistency and a lack of oversight, which have the potential to contribute to well-documented patterns of gender disparities in career advancement in academic medicine.

    View details for DOI 10.1001/jamanetworkopen.2021.25843

    View details for Web of Science ID 000698769200006

    View details for PubMedID 34542616

    View details for PubMedCentralID PMC8453318

  • Hepatitis C as a Potential Risk Factor for Adverse Surgical Outcomes in Head and Neck Free Tissue Transfer Reconstruction FACIAL PLASTIC SURGERY & AESTHETIC MEDICINE Callander, J. K., Strohl, M. P., Knott, P., Park, A., Seth, R., Heaton, C. M. 2022; 24 (4): 300-304

    Abstract

    Background: Infection with hepatitis C virus (HCV) is associated with an increased risk of developing head and neck cancer (HNC), and negatively impacts cancer-specific survival. Objective: To measure the impact of HCV status on free tissue transfer failure, flap takeback, and length of stay in HNC patients undergoing reconstruction. Methods: We retrospectively reviewed patients who underwent head and neck free tissue transfer reconstruction at a single academic institution between August 2011 and June 2020. Results: In the HCV-infected group, total flap failure rate was 2.9% versus 1.3% in the control group and the takeback rate was 11.1% versus 9.6%. On multivariate analysis, HCV status was not associated with flap failure, flap takeback, or total length of hospital stay >7 days. Conclusion: In this study, HCV status was not associated with differences in postoperative complications or length of stay. Future research with greater numbers of HCV-positive study subjects is required to elucidate the effect of HCV infection in this patient population.

    View details for DOI 10.1089/fpsam.2021.0082

    View details for Web of Science ID 000689742500001

    View details for PubMedID 34449263

  • Beyond Depth of Invasion: Adverse Pathologic Tumor Features in Early Oral Tongue Squamous Cell Carcinoma. The Laryngoscope Larson, A. R., Kemmer, J., Formeister, E., El-Sayed, I., Ha, P., George, J., Ryan, W., Chan, E., Heaton, C. 2020; 130 (7): 1715-1720

    Abstract

    In small (≤2 cm) oral tongue squamous cell carcinoma (OTSCC), we sought to clarify the contribution of pathologic features including perineural invasion (PNI), lymphovascular invasion (LVI), and worst pattern of invasion-5 (WPOI-5) to clinical outcomes relative to tumor depth of invasion (DOI) of > or ≤ 4 mm.Cases of ≤2 cm OTSCC treated surgically between 2000 and 2017 at an academic cancer center were reviewed, with retrospective pathologic slide review of DOI, LVI, PNI, and WPOI-5. Primary outcome measures included occult nodal positivity, 2-year locoregional recurrence (LRR), disease-specific survival (DSS), and overall survival (OS).One hundred tumors were included in analyses; 50 had DOI ≤ 4 mm, while 50 had DOI > 4 mm. When DOI was ≤4 mm, the presence of PNI, LVI, or WPOI-5 was not associated with higher rates of occult cervical metastasis, LRR, or OS. When DOI was >4 mm, there was no difference in rates of occult cervical metastasis or LRR with each feature. On multivariate analysis, only the presence of two or more adverse features was associated with higher LRR (OR 5.7, P = .01) and worse DSS (HR 6.5, P = .02).The rate of occult cervical metastases in small (≤2 cm) OTSCC when DOI is ≤4 mm is very low even when PNI, LVI, or WPOI-5 is present, and 2-year LRR is no different. When DOI is >4 mm, the strongest predictor of recurrence and survival on multivariate analysis is the presence of two or more features in the tumor.4 Laryngoscope, 130:1715-1720, 2020.

    View details for DOI 10.1002/lary.28241

    View details for PubMedID 31411752

  • Validation of the Postnatal Growth and Retinopathy of Prematurity Screening Criteria Binenbaum, G., Tomlinson, L. A., Campomanes, A., Bell, E. F., Donohue, P., Morrison, D., Quinn, G. E., Repka, M. X., Rogers, D., Yang, M. B., Yu, Y., Ying, G., Duros, T. B., Anh Nguyen, Maguire, M. G., Brightwell-Arnold, M., Shaffer, J., Blanco, M., Brown, T., Helker, C. P., Hutchinson, A., Young, C., McCourt, E., Lynch, A., Cathcart, J., Cerda, A., Bonnell, L., Thevarajah, T., Barry, G. P., Fisher, M., Battaglia, M. V., Drach, A., Hughes, K., Meyer, A., Gogal, C., Beitler, C., Centolanza, L., Moyer, K. T., Sobotor, M., Donohue, P., Repka, M. X., Shepard, J. A., Doherty, M., Reynolds, J. D., Connelly, E., Cheeseman, E., Shirer, K., Bradham, C., McAlpine, A., Sunthankar, S., Abbasian, J., Lim, J., Yang, M., Cobb, P., Alfano, E. L., Rogers, D., Reem, R. E., Schreckengost, A., Fellows, R. R., Loh, K., McGregor, M. A., Mustafa, T., Dean, I., Miller, R., Russell, T., Stattler, R., Maletic, S., Selph, T., Young, D., Siu, A., Kanemori, M., Kingston, G., Geloneck, M., Feldman, R., Baker, T., Baker, L., Melese, E., Haider, K., Wang, J., Hynes, E., Bell, E. F., Dumitrescu, A. V., Klein, J. M., Cress, G. A., Ajjarapu, A. S., Berge, K., Boeshart, E., Dorsey, M., Funk, B. M., Hach, G., Johnson, C. L., Kurian, K., Miller, E., Platt, A. C., Law, C., Gissing, A., Khazaeni, L., Dunbar, J., Hawkins, K., Lee, S., Sung, L., Leggitt, C., Ramasubramanian, A., Bhola, R., Bottorff, M., Dimova, N., Keith, R., Thomas, L., Anderson, J., Areaux, R. G., Holleschau, A., Gross, J., Kramer, A., Morrison, D., Donahue, S., Wilkins, C., Fukuda, N., Owings, S., Ruark, S., Siatkowski, R., Bhatti, F., Bergman, V., Corff, K., Harkey, K., Manfredo, A., Helmbrecht, A., Talsania, S., Whisenhunt, T., Suh, D., Berry, A., Lynes, D., Erikson, K. C., Binenbaum, G., Abbasi, S., Kirpalani, H., Quinn, G. E., Dawson, L., Tomlinson, L. A., Sylvester, C., Runkel, K., Runkel, L., Chen, W. S., Jackson, D., Davitt, B., Govreau, D., Breuer, L., Noonan, S., Hoffman, R., Beachy, J., Farnsworth, K., Farnsworth, K., Harrison, D., Bernhisel, A., Carlstrom, B., Campomanes, A., Bastea-Forte, Y., Sanchez, L., Kemmer, J., Neiman, A., Sitati-Ng'Anda, S., Tarczy-Hornoch, K., Baran, F., Eaton, L., Najm-Tehrani, N., Grossi, T., Isaac, M., Knighton, R., Khitri, M., Del Signore, M., Dembofsky, C., Meyer, A., Flaherty, K., Harris, T., Heeneke, J., Hendricks, D., Fecarotta, C. M., Fisher, A., Paullin, M., Zupancic, J., Postnatal Growth Retinopathy Prema AMER MEDICAL ASSOC. 2020: 31–37

    Abstract

    The first Postnatal Growth and Retinopathy of Prematurity Study (G-ROP-1) developed new screening criteria with 100% sensitivity for type 1 retinopathy of prematurity (ROP) and 30% reduction of infants requiring examinations in a retrospective development cohort of 7483 infants from 29 North American hospitals in 2006-2012. Infants meeting 1 or more of the following criteria undergo examinations: gestational age less than 28 weeks or birth weight less than 1051 g; weight gain less than 120 g during age 10 to 19 days, weight gain less than 180 g during age 20 to 29 days, or weight gain less than 170 g during age 30 to 39 days; or hydrocephalus.To evaluate the generalizability of the G-ROP screening criteria in a new cohort of at-risk infants.This prospective validation cohort study (G-ROP-2) was conducted at 41 hospitals in the United States and Canada (25 G-ROP-1 hospitals and 16 new hospitals) from September 8, 2015, to June 13, 2017, among 3981 premature infants at risk for ROP and with known ROP outcomes.Sensitivity for Early Treatment for Retinopathy of Prematurity Study type 1 ROP and potential reduction in infants receiving examinations.Among the 3981 infants in the study (1878 girls and 2103 boys; median gestational age, 28 weeks [range, 22-35 weeks]; median birth weight, 1072 g [range, 350-4080 g]; 1966 white; 942 black; 321 Latino; 120 Asian; 22 Native Hawaian or Pacific Islander; and 25 American Indian or Alaskan Native), the G-ROP criteria correctly predicted 219 of 219 cases of type 1 ROP (sensitivity, 100%; 95% CI, 98.3%-100%), while reducing the number of infants undergoing examinations by 35.6% (n = 1418). In a combined G-ROP-1 and G-ROP-2 cohort of 11 463 infants, the G-ROP criteria predicted 677 of 677 cases of type 1 ROP (sensitivity, 100%; 95% CI, 99.4%-100%), reducing the number of infants receiving examinations by 32.5% (n = 3730), while current criteria (birth weight <1501 g or gestational age ≤30 weeks 0 days) predicted 674 of 677 type 1 cases (sensitivity, 99.6%; 95% CI, 98.7%-99.8%).This study found that the G-ROP screening criteria were generalizable on validation and, if used clinically in the United States and Canada, could reduce the number of infants receiving examinations. The large G-ROP cohorts provide evidence-based screening criteria that have higher sensitivity and higher specificity (fewer infants receiving examinations) for type 1 ROP than currently recommended guidelines.

    View details for DOI 10.1001/jamaophthalmol.2019.4517

    View details for Web of Science ID 000506631600006

    View details for PubMedID 31725856

  • Perinatal Risk Factors for the Retinopathy of Prematurity in Postnatal Growth and Rop Study. Ophthalmic epidemiology Ying, G. S., Bell, E. F., Donohue, P., Tomlinson, L. A., Binenbaum, G. 2019; 26 (4): 270-278

    Abstract

    Objective: To evaluate perinatal risk factors for retinopathy of prematurity (ROP), in a large, broad-risk cohort of premature infants. Study design: Secondary analysis of data from the Postnatal Growth and ROP (G-ROP) Study, a retrospective cohort study of infants undergoing ROP examinations at 29 North American hospitals in 2006-2012. Results: Among 7483 infants, 3224 (43.1%) had any ROP and 931 (12.4%) had severe ROP (Type 1 or 2 ROP). In multivariable logistic regression analysis, significant risk factors for any ROP were lower birth weight (BW, odds ratio (OR) = 5.2, <501 g vs. >1250 g), younger gestational age (GA, OR = 32, <25 vs. >29 weeks), 1-min Apgar score <4 (OR = 1.2), race (OR = 1.6, White vs. Black), outborn (OR = 1.5), and delivery room intubation (OR = 1.3); and for severe ROP were lower BW (OR = 20, <501 g vs. >1250 g), younger GA (OR = 30, <25 vs. >29 weeks), male (OR = 1.5), Hispanic ethnicity (OR = 1.8), race (OR = 1.6, White vs. Black), outborn (OR = 1.6), and delivery room intubation (OR = 1.6). Together, these factors predicted well for any ROP (area under ROC curve (AUC) = 0.87) and severe ROP (AUC = 0.89), but BW and GA were the dominant factors for ROP (AUC = 0.86) and severe ROP (AUC = 0.88). Conclusions: Based on the largest report to date with detailed ROP data from infants meeting current screening guidelines, ROP risk is predominantly determined by the degree of prematurity at birth, with other perinatal factors contributing minimally.

    View details for DOI 10.1080/09286586.2019.1606259

    View details for PubMedID 31012360

  • Automated Smartphone Audiometry: A Preliminary Validation of a Bone-Conduction Threshold Test App ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY Dewyer, N. A., Jiradejvong, P., Lee, D. S., Kemmer, J. D., Sabes, J., Limb, C. J. 2019; 128 (6): 508-515

    Abstract

    To develop and validate an automated smartphone app that determines bone-conduction pure-tone thresholds.A novel app, called EarBone, was developed as an automated test to determine best-cochlea pure-tone bone-conduction thresholds using a smartphone driving a professional-grade bone oscillator. Adult, English-speaking patients who were undergoing audiometric assessment by audiologists at an academic health system as part of their prescribed care were invited to use the EarBone app. Best-ear bone-conduction thresholds determined by the app and the gold standard audiologist were compared.Forty subjects with varied hearing thresholds were tested. Sixty-one percent of app-determined thresholds were within 5 dB of audiologist-determined thresholds, and 79% were within 10 dB. Nearly all subjects required assistance with placing the bone oscillator on their mastoid.Best-cochlea bone-conduction thresholds determined by the EarBone automated smartphone audiometry app approximate those determined by an audiologist. This serves as a proof of concept for automated smartphone-based bone-conduction threshold testing. Further improvements, such as the addition of contralateral ear masking, are needed to make the app clinically useful.

    View details for DOI 10.1177/0003489419828770

    View details for Web of Science ID 000470664200004

    View details for PubMedID 30744390

  • Secondary Ocular Hypertension and the Risk of Glaucoma Surgery After Dexamethasone Intravitreal Implant in Routine Clinical Practice. Ophthalmic surgery, lasers & imaging retina Hemarat, K., Kemmer, J. D., Porco, T. C., Eaton, A. M., Khurana, R. N., Stewart, J. M. 2018; 49 (9): 680-685

    Abstract

    To determine the rate of ocular hypertension (OHT) after dexamethasone intravitreal implant in routine clinical practice and identify patient characteristics associated with a risk for glaucoma surgery.The charts of 260 eyes from 221 patients with diabetic macular edema, retinal vein occlusion, uveitis, and macular edema secondary to various causes treated with one or more dexamethasone implants were reviewed. Intraocular pressure (IOP), medications, and glaucoma interventions were collected before and after implantation.The mean baseline IOP was 14.3 mm Hg ± 3.6 mm Hg, and after receiving dexamethasone implant(s), 26.2% and 7.7% of patients had IOP greater than 25 mm Hg and 35 mm Hg, respectively. There was evidence (P < .001) of an association between preexisting glaucoma or glaucoma suspect status (103 eyes) and need for glaucoma surgery, and 4.62% (12 eyes) required glaucoma surgery.Secondary OHT induced by the dexamethasone implant can usually be controlled by medications, but the incidence of OHT requiring glaucoma surgery was high (4.62%) in our study relative to rates previously reported in the literature. All patients, especially those with preexisting glaucoma, should be advised of the possible need for glaucoma surgery prior to undergoing treatment with the dexamethasone implant. [Ophthalmic Surg Lasers Imaging Retina. 2018;49:680-685.].

    View details for DOI 10.3928/23258160-20180831-05

    View details for PubMedID 30222802

  • Development of Modified Screening Criteria for Retinopathy of Prematurity: Primary Results From the Postnatal Growth and Retinopathy of Prematurity Study. JAMA ophthalmology Binenbaum, G., Bell, E. F., Donohue, P., Quinn, G., Shaffer, J., Tomlinson, L. A., Ying, G. S. 2018; 136 (9): 1034-1040

    Abstract

    Current retinopathy of prematurity (ROP) guidelines, which are based on studies of high-risk infants and expert opinion, have low specificity for disease requiring treatment. Postnatal weight gain-based models improve specificity but have been limited by complexity and small development cohorts, which results in model overfitting and resultant decreased sensitivity in validation studies.To develop a birth weight (BW), gestational age (GA), and weight gain (WG) prediction model using data from a broad-risk cohort of premature infants.The Postnatal Growth and ROP Study was a retrospective multicenter cohort study conducted in 29 hospitals in the United States and Canada from 2006 to 2012 that included 7483 premature infants at risk for ROP with a known ROP outcome. A hybrid modeling approach was used that combined BW/GA criteria, weight comparison with expected growth from infants without ROP, multiple growth-interval assessments, consideration of nonphysiological WG, and user-friendly screening criteria. Numerous BW/GA levels, postnatal age periods, time intervals, and WG percentile thresholds were evaluated to identify the most robust parameters.Sensitivity for Early Treatment of ROP Study type 1 ROP and potential reduction in infants who require examinations.Of 7483 infants, the median (SD) BW was 1099 (359) g, the median GA was 28 weeks (range, 22-35), 3575 (47.8%) were female, 3615 (48.4%) were white, 2310 (30.9%) were black, 233 (3.1%) were Asian, 93 (1.2%) were Pacific Islander, and 40 (0.5%) were American Indian/Alaskan Native. Infants who met any of 6 criteria would undergo examinations: (1) a GA of younger than 28 weeks; (2) a BW of less than 1051 g; a WG of less than 120 g, 180 g, or 170 g during ages 10 to 19, 20 to 29, or 30 to 39 days, respectively; or hydrocephalus. These criteria predicted 459 of 459 (100%) type 1 (sensitivity, 100%; 95% CI, 99.2%-100%), 524 of 524 (100%) treated, and 466 of 472 (98.7%) type 2 cases while reducing the number of infants who required examinations by 2269 (30.3%).This cohort study, broadly representative of infants who are undergoing ROP examinations, provides evidence-based screening criteria. With validation, the Postnatal Growth and ROP Study criteria could be incorporated into ROP screening guidelines to reduce the number of infants who require examinations in North America.

    View details for DOI 10.1001/jamaophthalmol.2018.2753

    View details for PubMedID 30003216

    View details for PubMedCentralID PMC6142979

  • BET Inhibition Overcomes Receptor Tyrosine Kinase-Mediated Cetuximab Resistance in HNSCC. Cancer research Leonard, B., Brand, T. M., O'Keefe, R. A., Lee, E. D., Zeng, Y., Kemmer, J. D., Li, H., Grandis, J. R., Bhola, N. E. 2018; 78 (15): 4331-4343

    Abstract

    Cetuximab, the FDA-approved anti-EGFR antibody for head and neck squamous cell carcinoma (HNSCC), has displayed limited efficacy due to the emergence of intrinsic and acquired resistance. We and others have demonstrated that cetuximab resistance in HNSCC is driven by alternative receptor tyrosine kinases (RTK), including HER3, MET, and AXL. In an effort to overcome cetuximab resistance and circumvent toxicities associated with the administration of multiple RTK inhibitors, we sought to identify a common molecular target that regulates expression of multiple RTK. Bromodomain-containing protein-4 (BRD4) has been shown to regulate the transcription of various RTK in the context of resistance to PI3K and HER2 inhibition in breast cancer models. We hypothesized that, in HNSCC, targeting BRD4 could overcome cetuximab resistance by depleting alternative RTK expression. We generated independent models of cetuximab resistance in HNSCC cell lines and interrogated their RTK and BRD4 expression profiles. Cetuximab-resistant clones displayed increased expression and activation of several RTK, such as MET and AXL, as well as an increased percentage of BRD4-expressing cells. Both genetic and pharmacologic inhibition of BRD4 abrogated cell viability in models of acquired and intrinsic cetuximab resistance and was associated with a robust decrease in alternative RTK expression by cetuximab. Combined treatment with cetuximab and bromodomain inhibitor JQ1 significantly delayed acquired resistance and RTK upregulation in patient-derived xenograft models of HNSCC. These findings indicate that the combination of cetuximab and bromodomain inhibition may be a promising therapeutic strategy for patients with HNSCC.Significance: Inhibition of bromodomain protein BRD4 represents a potential therapeutic strategy to circumvent the toxicities and financial burden of targeting the multiple receptor tyrosine kinases that drive cetuximab resistance in HNSCC and NSCLC.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/15/4331/F1.large.jpg Cancer Res; 78(15); 4331-43. ©2018 AACR.

    View details for DOI 10.1158/0008-5472.CAN-18-0459

    View details for PubMedID 29792310

    View details for PubMedCentralID PMC6072571

  • Leveraging Genomics for Head and Neck Cancer Treatment. Journal of dental research Kemmer, J. D., Johnson, D. E., Grandis, J. R. 2018; 97 (6): 603-613

    Abstract

    The genomic landscape of head and neck squamous cell carcinoma (HNSCC) has been recently elucidated. Key epigenetic and genetic characteristics of this cancer have been reported and substantiated in multiple data sets, including those distinctive to the growing subset of human papilloma virus (HPV)-associated tumors. This increased understanding of the molecular underpinnings of HNSCC has not resulted in new approaches to treatment. Three Food and Drug Administration-approved molecular targeting agents are currently available to treat recurrent/metastatic disease, but these have exhibited efficacy only in subsets of HNSCC patients, and thus surgery, chemotherapy, and/or radiation remain as standard approaches. The lack of predictive biomarkers to any therapy represents an obstacle to achieving the promise of precision medicine. This review aims to familiarize the reader with current insights into the HNSCC genomic landscape, discuss the currently approved and promising molecular targeting agents under exploration in laboratories and clinics, and consider precision medicine approaches to HNSCC.

    View details for DOI 10.1177/0022034518756352

    View details for PubMedID 29420101

    View details for PubMedCentralID PMC5960879

  • Ocular complications following treatment in the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Study. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus Morrison, D., Shaffer, J., Ying, G. S., Binenbaum, G. 2018; 22 (2): 128-133

    Abstract

    To determine the prevalence of treatment-related ocular complications and disease progression following treatment for retinopathy of prematurity (ROP).This was a retrospective cohort study of eyes treated for ROP at 29 North American neonatal intensive care units in the Postnatal Growth and ROP (G-ROP) Study. Data from the time of treatment through 15 months were abstracted from medical records by certified data collectors. Treatment-related complication (cataract, hyphema, glaucoma, corneal abrasion/opacity), and disease-progression (retinal fold, dragging, or stage 4 or 5 detachment) were calculated by treatment modality. Vitreous hemorrhage was classified separately, because it can relate to treatment or disease progression.Of 7,483 infants included in the study, 1,004 eyes (512 infants) underwent ROP treatment: 970 eyes received laser as initial therapy; 34 eyes received intravitreal bevacizumab (IVB). Median follow-up after treatment was 18 weeks. Overall, one or more complications occurred in 2.6% (95% CI, 1.8%-3.8%) laser treated eyes and no (0%; 95% CI, 0.0%-10.1%) IVB eyes. Disease-progression occurred in 9.2% (95% CI, 7.6%-11.2%) laser treated eyes, no (0%; 95% CI, 0.0-12.9%) IVB-only eyes. Vitreous hemorrhage occurred in 5.4% (95% CI: 4.1% - 7.0%) laser treated eyes, no IVB-only eyes.Rates of complications are very low following ROP treatment with either laser or IVB. Of laser-treated eyes, 9% experienced disease progression despite treatment.

    View details for DOI 10.1016/j.jaapos.2017.12.005

    View details for PubMedID 29548840

    View details for PubMedCentralID PMC5915915

  • Comprehensive characterization of DNA methylation changes in Fuchs endothelial corneal dystrophy. PloS one Khuc, E., Bainer, R., Wolf, M., Clay, S. M., Weisenberger, D. J., Kemmer, J., Weaver, V. M., Hwang, D. G., Chan, M. F. 2017; 12 (4): e0175112

    Abstract

    Transparency of the human cornea is necessary for vision. Fuchs Endothelial Corneal Dystrophy (FECD) is a bilateral, heritable degeneration of the corneal endothelium, and a leading indication for corneal transplantation in developed countries. While the early onset, and rarer, form of FECD has been linked to COL8A2 mutations, the more common, late onset form of FECD has genetic mutations linked to only a minority of cases. Epigenetic modifications that occur in FECD are unknown. Here, we report on and compare the DNA methylation landscape of normal human corneal endothelial (CE) tissue and CE from FECD patients using the Illumina Infinium HumanMethylation450 (HM450) DNA methylation array. We show that DNA methylation profiles are distinct between control and FECD samples. Differentially methylated probes (10,961) were identified in the FECD samples compared with the control samples, with the majority of probes being hypermethylated in the FECD samples. Genes containing differentially methylated sites were disproportionately annotated to ontological categories involving cytoskeletal organization, ion transport, hematopoetic cell differentiation, and cellular metabolism. Our results suggest that altered DNA methylation patterns may contribute to loss of corneal transparency in FECD through a global accumulation of sporadic DNA methylation changes in genes critical to basic CE biological processes.

    View details for DOI 10.1371/journal.pone.0175112

    View details for PubMedID 28384203

    View details for PubMedCentralID PMC5383226